Health
Gout medication reduces major cardiovascular events in heart patients – News-Medical.Net
Colchicine reduces the risk of major cardiovascular events in patients with chronic coronary disease, according to results of the LoDoCo2 trial presented in a Hot Line session today at ESC Congress 2020.
Reviewed by Emily Henderson, B.Sc.Aug 31 2020
Colchicine reduces the risk of major cardiovascular events in patients with chronic coronary disease, according to results of the LoDoCo2 trial presented in a Hot Line session today at ESC Congress 2020.
Over a decade, more than one in three heart patients will have another heart attack or stroke, or die from heart disease, despite taking preventive medication. Our study shows that this could be reduced to one in four with the addition of low-dose …
-
General22 hours agoRussia launches hundreds of drones and missiles against Ukraine in fresh attack
-
Business15 hours agoWhy did this ASX 200 healthcare stock crash 14% yesterday?
-
Business17 hours agoOwn Xero shares? Here are 3 key takeaways from its AGM
-
Business14 hours agoHere’s what analysts expect for the BHP share price in the coming year